StocksMedium•5 November 2026•
1 min read
Edwards Lifesciences Wins FDA Approvals for PASCAL and EVOQUE Heart Systems
Key Facts
1Edwards Lifesciences secured U.S. FDA approval for its PASCAL Precision tricuspid repair and PASCAL Ace mitral repair systems.
2The EVOQUE transjugular access system received regulatory approvals in both the United States and Europe.
Edwards Lifesciences secured U.S. FDA approval for its PASCAL Precision tricuspid repair and PASCAL Ace mitral repair systems. Benzinga reported that the EVOQUE transjugular access system also received regulatory approvals in both the United States and Europe, expanding the company's structural heart portfolio.
EW closed at $99.37 on November 4, 2026, with the stock reaching a session high of $100.25 and a low of $96.72. These approvals follow clinical evaluations of the systems designed to enhance treatment options for heart valve repair.